Incyte (INCY): financials, SEC filings and peers
Incyte (INCY) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Wilmington, Delaware.
It was founded in 1991 and joined the S&P 500 on February 28, 2017.
Its fiscal year ends in December, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Services-Commercial Physical & Biological Research”.
Incyte at a glance
- Revenue (12 months)
- $6.0B
- Revenue growth
- +24.9%
- Operating margin
- 10.4%
- Net income (12 months)
- $403M
- Free cash flow (12 months)
- —
- Cash
- $3.3B
- Debt
- —
- Diluted EPS (12 months)
- $1.88
Twelve months to September 30, 2026, from the 10-Q filed October 29, 2026.
Latest twelve months
Over the twelve months to September 30, 2026, Incyte reported revenue of $6.0 billion, up 24.9% from a year earlier.
Its operating margin was 10.4%, down 20.3 percentage points from a year earlier: for every $100 of sales, about $10 was left as operating profit.
Net income was $403 million (6.7% of revenue), 66.1% lower than a year earlier.
Profit fell while sales grew, which usually points to higher costs, heavier investment or one-time items. The filings explain which.
At the end of the period it held $3.3 billion in cash and not reported in debt, a net cash position of $3.3 billion.
Five-year trend
- Revenue went from $2.7 billion in fiscal 2020 to $5.1 billion in fiscal 2025, about 14.0% a year.
- Revenue has grown for 5 fiscal years in a row.
- Operating margin widened from -9.9% to 29.5% over the same years.
- Free cash flow was negative in 1 of the last 3 fiscal years.
- Incyte reported a net loss in 1 of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B |
| Revenue growth | 12.0% | 13.7% | 8.9% | 14.8% | 21.2% |
| Operating margin | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% |
| Net income | $949M | $341M | $598M | $33M | $1.3B |
| Free cash flow | $568M | $892M | — | — | — |
| Diluted EPS | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
Fiscal years as reported in Incyte’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed October 29, 2026 — quarterly report
- 8-K filed October 29, 2026 — Earnings results
- 8-K filed August 31, 2026 — Other event
- 10-Q filed July 28, 2026 — quarterly report
- 8-K filed July 28, 2026 — Earnings results
- 8-K filed July 6, 2026 — Other event
- 8-K filed June 22, 2026 — Other event
- 8-K filed June 9, 2026 — Shareholder vote results
Companies like Incyte
Other S&P 500 companies in Biotechnology:
- ABBVAbbVieNorth Chicago, Illinois
- AMGNAmgenThousand Oaks, California
- BIIBBiogenCambridge, Massachusetts
- GILDGilead SciencesFoster City, California
- MRNAModernaCambridge, Massachusetts
- REGNRegeneron PharmaceuticalsTarrytown, New York
- VRTXVertex PharmaceuticalsBoston, Massachusetts
More from Health Care
Questions about Incyte
Is Incyte's revenue growing?
Yes. Revenue for the twelve months to September 30, 2026 was $6.0 billion, up 24.9% from a year earlier, according to its SEC filings.
Is Incyte profitable?
Yes. It earned $403 million in net income over the twelve months to September 30, 2026, a net margin of 6.7%.
When did Incyte last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on October 29, 2026.
Which companies are similar to Incyte?
In the S&P 500, Incyte is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Amgen (AMGN), Biogen (BIIB), Gilead Sciences (GILD), Moderna (MRNA) are in the same group.
Understand the numbers
Source: Incyte’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 10, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.